CoMentis Company
AmCyte develops encapsulated proliferated human islets for transplantation into patients with diabetes. The company specializes in adult stem cell research to treat diabetes with islet replacement therapy.
Investors
%20.jpg)
%20.jpg)
Total Funding:
$107.5M
Headquarters:
United States
Funding Status:
Late Stage Venture
Employee Number:
51-100
Investment Stage:
N/A
Last Funding Type:
Series E
Number Of Exists:
N/A
Technology:
Stem Cell
Investor Type:
N/A
Investors Number:
14
Founded Date:
2004
Industry:
Regenerative medicine